Want to see HK:2633 full AI Analyst Report?
2633 Stock Chart & Stats
HK$1.29
HK$0.01(0.99%)
At close: 4:00 PM EST
HK$1.29
HK$0.01(0.99%)
Day’s Range― - ―
52-Week RangeHK$0.98 - HK$1.78
Previous CloseN/A
Volume1.98M
Average Volume (3M)821.71K
Market Cap
HK$1.98B
Enterprise ValueHK$2.69B
Total Cash (Recent Filing)HK$395.06M
Total Debt (Recent Filing)HK$904.62M
Price to Earnings (P/E)6.9
Beta0.11
Next Earnings
Nov 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield15.4%
Share Statistics
EPS (TTM)0.15
Shares Outstanding2,000,221,000
10 Day Avg. Volume1,775,382
30 Day Avg. Volume821,706
Financial Highlights & Ratios
PEG Ratio0.06
Price to Book (P/B)0.96
Price to Sales (P/S)1.49
P/FCF Ratio8.42
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
HK$2.45Price Target Upside89.92% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)0.15
Revenue Forecast (FY)HK$1.64B
Bulls Say, Bears Say
Bulls Say
Cash GenerationConsistent operating cash flow and growing free cash flow provide durable internal funding for R&D, manufacturing and dividend/return programs. Reliable cash generation increases strategic optionality, supports reinvestment without excess external financing, and improves resilience over 2–6 months.
Profitability And MarginsSustained healthy gross, net and EBITDA margins indicate effective cost control and pricing power in core products. Margin durability supports consistent earnings conversion, funds incremental investments, and cushions against cyclical revenue swings, strengthening long-term operational stability.
Balance Sheet StrengthA solid equity base and favorable ROE signal efficient use of capital and lower solvency risk. This balance sheet profile preserves financial flexibility for capex, product launches or acquisitions, and reduces refinancing vulnerability across the medium term.
Bears Say
Recent Revenue DipA recent slight revenue decline interrupts growth momentum and could reflect product lifecycle headwinds or competitive pressure. If persistent, revenue weakness can erode operating leverage, constrain reinvestment capacity, and make funding growth initiatives or maintaining margins harder over the medium term.
Moderate LeverageModerate leverage limits financial flexibility and increases exposure to interest cost swings. During slower revenue periods or higher rates, debt servicing can crowd out investment or dividends, making careful balance sheet management necessary to preserve capacity for strategic spending and shocks.
Capex VariabilityVariable capital spending creates free cash flow volatility and complicates long-term planning. Fluctuating capex can lead to uneven reinvestment in manufacturing or product development, potentially delaying growth initiatives or creating short windows of cash strain across the 2–6 month horizon.
Jacobson Pharma Corporation Limited News
2633 FAQ
What was Jacobson Pharma Corporation Limited’s price range in the past 12 months?
Jacobson Pharma Corporation Limited lowest stock price was HK$0.98 and its highest was HK$1.78 in the past 12 months.
What is Jacobson Pharma Corporation Limited’s market cap?
Jacobson Pharma Corporation Limited’s market cap is HK$1.98B.
When is Jacobson Pharma Corporation Limited’s upcoming earnings report date?
Jacobson Pharma Corporation Limited’s upcoming earnings report date is Nov 20, 2026 which is in 141 days.
How were Jacobson Pharma Corporation Limited’s earnings last quarter?
Jacobson Pharma Corporation Limited released its earnings results on Jun 23, 2026. The company reported HK$0.08 earnings per share for the quarter, beating the consensus estimate of N/A by HK$0.08.
Is Jacobson Pharma Corporation Limited overvalued?
According to Wall Street analysts Jacobson Pharma Corporation Limited’s price is currently Undervalued.
Does Jacobson Pharma Corporation Limited pay dividends?
Jacobson Pharma Corporation Limited pays a Semiannually dividend of HK$0.048 which represents an annual dividend yield of 15.4%. See more information on Jacobson Pharma Corporation Limited dividends here
What is Jacobson Pharma Corporation Limited’s EPS estimate?
Jacobson Pharma Corporation Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Jacobson Pharma Corporation Limited have?
Jacobson Pharma Corporation Limited has 2,000,221,000 shares outstanding.
What happened to Jacobson Pharma Corporation Limited’s price movement after its last earnings report?
Jacobson Pharma Corporation Limited reported an EPS of HK$0.08 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went down -2.727%.
Which hedge fund is a major shareholder of Jacobson Pharma Corporation Limited?
Currently, no hedge funds are holding shares in HK:2633
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Jacobson Pharma Corporation Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
HK$2.45 (89.92% Upside)
HK$2.45 (89.92% Upside)
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
80.83%
12-Months-Change
Fundamentals
Return on Equity
12.91%
Trailing 12-Months
Asset Growth
-2.23%
Trailing 12-Months
Company Description
Jacobson Pharma Corporation Limited
Jacobson Pharma Corporation Limited, a subsidiary of Kingshill Development Limited, specializes in the production, promotion, and distribution of generic medications and branded healthcare products. Its market reach extends across Hong Kong, mainland China, Macau, Singapore, and international territories. The company offers a broad selection of generic pharmaceuticals targeting diverse medical conditions, including respiratory, cardiovascular, central nervous system, gastrointestinal, genito-urinary, musculoskeletal, endocrine and metabolic, dermatological, anti-allergic, scar treatment, oral anti-diabetic, and anti-infective categories. Specific examples comprise arsenic trioxide oral solutions, rosuvastatin tablets, and atorvastatin tablets. In addition to generics, the company provides branded medications, health and wellness products, and traditional Chinese remedies. Prominent proprietary Chinese medicines include Po Chai pills, Ho Chai Kung Tji Thung San, Tong Tai Chung Woodlok oil, Flying Eagle Woodlok Oil, Saplingtan, Shiling oil, Contractubex, Doan's Ointment, and Col-gan tablets. Its operations also extend to trading medical provisions, procuring packaging materials, distributing herbal and health-related goods, conducting research and development, and managing property holdings. The company distributes its offerings to a wide range of clients, including hospitals, clinics, authorized pharmacies, independent physicians, retail outlets, and trading companies. Founded in 2016, Jacobson Pharma Corporation Limited is headquartered in Kwun Tong, Hong Kong.
2633 Stock 12 Month Forecast
Average Price Target
HK$2.45
▲(89.92% Upside)
Technical Analysis
China Traditional Chinese Medicine Holdings Co
―
Wai Yuen Tong Medicine Holdings Limited
―
PuraPharm Corp. Ltd.
―
Dawnrays Pharmaceutical Holdings Ltd.
―
Pak Fah Yeow International Limited
―
Options Prices
Currently, No data available
---